Steven Gannon - 12 May 2026 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Reporting relationship: Director
Issuer ticker: XENE
Reported as of: 12 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 May 2026, 21:40:43 UTC
Prior SEC filing: 06 Jun 2025
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Nathaniel Adams, Attorney-in-fact

Key filing fact

Steven Gannon filed Form 4 for Xenon Pharmaceuticals Inc. (XENE) on 13 May 2026.

Key facts

This page summarizes Steven Gannon's Form 4 filing for Xenon Pharmaceuticals Inc. (XENE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 May 2026, 21:40.

Change

Previous filing in this sequence was filed on 06 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001643085 Primary reporting owner

GANNON STEVEN

Relationship: Director
Address: 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA
Signature: /s/ Nathaniel Adams, Attorney-in-fact
Signature date: 13 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XENE transaction

Common Shares

Options Exercise

Transaction value
Shares: +3,500
Change %: +49%
Price: $7.38^*
Shares after: 10,641
Date: 12 May 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XENE transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -3,500
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 12 May 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 3,500
Exercise price: $7.38
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option are fully vested and exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .